Skip to content

Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026

October 1, 2026 · 10 min

Show notes

Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.

In this episode
  1. CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip

    CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment # CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment Dr. SkinnyVIP September 15, 2026 ~9 min read Formulary details current as of September 15, 2026 This guide summarizes CVS Caremark’s May 28, 2026 announcement and standard commercial formulary template as of the…

  2. Critics say GLP-1 coverage shift raises equity issues — The Boston Globe

    # Critics say GLP-1 coverage shift raises equity issues Author: Alison Kuznitz Published: 2026-09-30T21:56:03.616000+00:00 Source: bostonglobe.com (bostonglobe.com) Language: en ## Story Critics say GLP-1 coverage shift raises equity issues # Critics say GLP-1 coverage shift raises equity issues A woman holds a Wegovy injector pen in her Wenatchee, Wash., home, on June 3, 2024. M. SCOTT…

  3. Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics

    # Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version Published: 2026-09-30T14:00:00+00:00 Source: drugtopics.com (drugtopics.com) Language: en ## Story --- ## title: "Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version" description: "Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled…

  4. Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!

    Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study # Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study By PR Newswire | September 30, 2026,…

  5. Newsom signs law allowing California-made GLP-1 drugs — Redding

    Newsom signs law allowing California-made GLP-1 drugs # California’s GLP-1 law could expand access to obesity treatment Ernesto Centeno Araujo USA TODAY NETWORK Sept. 29, 2026, 4:42 p.m. PT Gov. Gavin Newsom recently signed a law that would allow California to make and distribute a generic version of a popular class of weight-loss drugs through the state's CalRx program. California…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

All episodes of GLP-1 Daily: Ozempic & Wegovy News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.